Print

IGBA Reiterates its Yearly Call to Join the Biosimilars Movement on Advancing Access (November 2022)

Geneva, November 14, 2022 – In the week ahead, IGBA will renew its commitment to the collaborative effort to establish worldwide biosimilar policies that deliver better health outcomes and biologics access equity for more patients. The third Global Biosimilars Week will run from 14th to 18th November, 2022 on social media, supported by a rich resource dedicated website globalbiosimilarsweek.org.

Print

IGBA’s CEO Advisory Committee Meets with WHO Director General and WHO Leadership (October 2022)

The International Generic and Biosimilar Medicines Association’s (IGBA) newly established CEO Advisory Committee held its first in-person meeting in Geneva this week and had a far-reaching exchange with the World Health Organization’s (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus and other WHO leaders. This was the first opportunity for Dr. Tedros to engage in a direct dialogue with the IGBA CEO Advisory Committee following its launch and the admission of IGBA as a non-State actor in official relations with WHO earlier this year.

Share this page!

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on: Twitter - LinkedIn - YouTube

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site